Patent intelligence · WO
WO 2025068985
DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5
DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5
Patent details — WO 2025068985
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Apr 3, 2025
- Expiration
- Mar 29, 2045
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- CPC classes
- A61K 31/ 502 A I, A61P 35/ 00 A I, A61P/3500
Quick answer
WO 2025068985 (DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Apr 3, 2025. Expires Mar 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEIGENE SWITZERLAND GMBH [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 502 A I, A61P 35/ 00 A I, A61P/3500
More from BEIGENE SWITZERLAND GMBH [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
granted -
AU 2025242171
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
granted -
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
granted -
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
granted -
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
granted -
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
granted -
US 2025304535
KAT6 Inhibitors
granted -
US 2025290040
GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE
granted
Frequently asked questions
What is US patent 2025068985?
WO 2025068985 (DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Apr 3, 2025. Expires Mar 29, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025068985?
BEIGENE SWITZERLAND GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025068985 expire?
Our index shows an expiration date of Mar 29, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.